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Veterinary use of the nonsteroidal anti-inflammatory (NSAID) drug diclofenac in South Asia has resulted in the collapse
of populations of three vulture species of the genus Gyps to the most severe category of global extinction risk. Vultures
are exposed to diclofenac when scavenging on livestock treated with the drug shortly before death. Diclofenac causes
kidney damage, increased serum uric acid concentrations, visceral gout, and death. Concern about this issue led the
Indian Government to announce its intention to ban the veterinary use of diclofenac by September 2005.
Implementation of a ban is still in progress late in 2005, and to facilitate this we sought potential alternative NSAIDs by
obtaining information from captive bird collections worldwide. We found that the NSAID meloxicam had been
administered to 35 captive Gyps vultures with no apparent ill effects. We then undertook a phased programme of
safety testing of meloxicam on the African white-backed vulture Gyps africanus, which we had previously established
to be as susceptible to diclofenac poisoning as the endangered Asian Gyps vultures. We estimated the likely maximum
level of exposure (MLE) of wild vultures and dosed birds by gavage (oral administration) with increasing quantities of
the drug until the likely MLE was exceeded in a sample of 40 G. africanus. Subsequently, six G. africanus were fed
tissues from cattle which had been treated with a higher than standard veterinary course of meloxicam prior to death.
In the final phase, ten Asian vultures of two of the endangered species (Gyps bengalensis, Gyps indicus) were dosed
with meloxicam by gavage; five of them at more than the likely MLE dosage. All meloxicam-treated birds survived all
treatments, and none suffered any obvious clinical effects. Serum uric acid concentrations remained within the normal
limits throughout, and were significantly lower than those from birds treated with diclofenac in other studies. We
conclude that meloxicam is of low toxicity to Gyps vultures and that its use in place of diclofenac would reduce vulture
mortality substantially in the Indian subcontinent. Meloxicam is already available for veterinary use in India.
Citation: Swan G, Naidoo V, Cuthbert R, Green RE, Pain DJ, et al. (2006) Removing the threat of diclofenac to critically endangered Asian vultures. PLoS Biol 4(3): e66.
Introduction
Veterinary use of the nonsteroidal anti-inﬂammatory drug
(NSAID) diclofenac is a major cause of the catastrophic
collapse of Gyps vulture populations in the Indian subcon-
tinent [1–3]. Three species of vultures endemic to South Asia,
which together used to number tens of millions, are now at
high risk of global extinction and are listed as critically
endangered [4]. Populations of Oriental white-backed (Gyps
bengalensis), long-billed (Gyps indicus) and slender-billed vul-
tures (Gyps tenuirostris) have declined by more than 95% since
the early 1990s [5,6], and continue to decline at an annual
rate of 22% to 48% [3].
Diclofenac is a widely available veterinary drug in the
Indian subcontinent, where it is used for the symptomatic
treatment and management of inﬂammation, fever, and/or
pain associated with disease or injury in domestic livestock.
Vultures are exposed to the drug when they consume
carcasses of cattle that were treated with diclofenac shortly
before death. Following experimental exposure to diclofenac
or diclofenac-contaminated tissues, Gyps vultures die within
days from kidney failure with clinical signs of extensive
visceral gout (formation of uric acid crystals within tissue)
[1,7]. These clinical signs and diclofenac residues in vulture
tissues have been found in carcasses of wild Gyps vultures
from across India, Pakistan, and Nepal [1,2], and the
proportion of vulture carcasses with signs of diclofenac
poisoning is consistent with this being the main, and possibly
the only, cause of the vulture decline [3].
The loss of tens of millions of vultures over the last decade
has had major ecological consequences across the Indian
subcontinent that pose a potential threat to human health. In
many places, populations of feral dogs (Canis familiaris) have
beneﬁted from the disappearance of Gyps vultures as the main
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scavenger of wild and domestic ungulate carcasses [8].
Associated with the rise in dog numbers [9] is an increased
risk of human cases of rabies. If rat (Rattus spp.) populations
also increase at carcass dumps in and near settlements, the
risk of transmission of diseases, including bubonic plague, to
humans may also increase. Vultures probably also helped to
control livestock diseases, such as brucellosis, tuberculosis,
and anthrax by disposing of infected carcasses [10,11]. The
loss of vultures has had a social impact on the Indian
Zoroastrian Parsi community, who traditionally use vultures
to dispose of human corpses in ‘‘sky burials’’ [12] and are now
having to seek alternative disposal methods [13]. As a
consequence of the collapse of vulture populations, national
and international conservation organisations have concluded
that it is essential to ban the use of diclofenac in livestock so
as to remove it as a contaminant of the food of wild vultures
[14]. At a meeting of the National Wildlife Board in March
2005, the Government of India announced that it intended to
phase out the veterinary use of diclofenac [15].
The identiﬁcation of NSAIDs that are effective for the
treatment of livestock, but also relatively nontoxic to
vultures, would facilitate the removal of diclofenac from the
food of vultures. NSAIDs are characterised by their ability to
inhibit cyclo-oxygenase enzymes, which are involved in the
formation of prostaglandins. However, there are marked
differences between drugs in their selective inhibition of the
two subtypes of cyclo-oxygenase COX-1 and COX-2, with the
latter being involved with the modulation of inﬂammatory
responses and pain, while the former modulates blood ﬂow to
the kidneys. The ability of NSAIDs to inhibit both these
subtypes has been implicated as a cause of the severe side
effects occasionally associated with the use of some NSAIDs
[16]. Toxic effects on the kidneys of birds have been observed
following treatment with a number of NSAIDs [1,17].
However, there are marked interspeciﬁc differences in
toxicity [18–20], and it is necessary to establish the safety of
individual NSAIDs to Gyps vultures. To identify candidate
alternative drugs, we contacted veterinarians at zoos and
wildlife rehabilitation centres worldwide and requested
information on the clinical use of NSAIDs on captive Gyps
vultures, including the outcome of such treatment. Prelimi-
nary results suggested that the NSAID meloxicam is a
potential alternative for diclofenac, because 35 individuals
from six Gyps species (including ﬁve Oriental white-backed
vultures) treated with meloxicam, typically at doses of 0.2–0.5
mg kg1, showed no ill effects; while the use of several other
NSAIDs was associated with renal failure (unpublished data).
As all three of the resident Asian Gyps vultures are critically
endangered, we considered it unacceptable to use these
species for safety testing without ﬁrst evaluating the safety of
meloxicam on a suitable surrogate. The African white-backed
vulture (Gyps africanus) was chosen as a surrogate because it
has a favourable global conservation status (category Least
Concern) [4], and diclofenac has been shown experimentally
to be as toxic to it as it is to the endangered G. bengalensis [7].
Clinical signs at postmortem examination of experimentally
dosed birds indicate a similar mechanism of toxicity in both
species. Diclofenac-dosed G. africanus showed signiﬁcant
increases in serum uric acid concentrations 12–24 h after
dosing and exhibited lethargy and neck-drooping behaviour
before death [7].
In this paper, we report tests on the safety of meloxicam to
Gyps vultures, which we dosed with meloxicam by gavage (oral
administration) and by feeding them with tissue from
meloxicam-dosed cattle. Using both routes of drug admin-
istration, the range of dose levels exceeded our estimated
likely maximum level of exposure (MLE) of meloxicam to wild
vultures. To minimise the risk of suffering and death of
experimental animals, safety testing was undertaken in six
phases (summarised in Table 1). During the ﬁrst three phases,
the dose rate of meloxicam administered by gavage to G.
africanus was progressively increased from 0.5 mg kg1 vulture
Table 1. Summary of Results and Experimental Schedule for the Testing of the NSAIDs Diclofenac and Meloxicam on G. bengalensis
and G. indicus Vultures, and on the Nonthreatened G. africanus
Gyps Species NSAID Phase Dose (mg kg1) Route N Dosed N Died % Mortality N Control Status and Source of Birds
G. bengalensis Diclofenac — 0.007 to 0.940 Fed treated tissue 20 13 65 — Captive birds (Pakistan)a
G. bengalensis Diclofenac — 0.25 and 2.5 Gavage 4 3 75 2 Captive birds (Pakistan)a
G. africanus Diclofenac — 0.8 Gavage 2 2 100 2 Captive birds (South Africa)b
G. africanus Meloxicam I 0.5 Gavage 5 0 0 3 Captive birds (South Africa)
G. africanus Meloxicam II 1.0 Gavage 5 0 0 3 Captive birds (South Africa)
G. africanus Meloxicam III 2.0 Gavage 5 0 0 3 Captive birds (South Africa)
G. africanus Meloxicam IV.1 2.0 Gavage 14c 0 0 — Captive birds (South Africa)
G. africanus Meloxicam IV.2 2.0 Gavage 21 0 0 4 Wild-caught birds (Namibia)
G. africanus Meloxicam V 0.03 to 1.98 Fed treated tissue 6d 0 0 — Captive birds (South Africa)
G. africanus Meloxicam V 1.18 to 2.45 Gavage 6d 0 0 — Captive birds (South Africa)
G. bengalensis Meloxicam VI 0.5 Gavage 3 0 0 1 Captive birds (India)
G. bengalensis Meloxicam VI 2.0 Gavage 3 0 0 1 Captive birds (India)
G. indicus Meloxicam VI 0.5 Gavage 2 0 0 2 Captive birds (India)
G. indicus Meloxicam VI 2.0 Gavage 2 0 0 1 Captive birds (India)
There was no mortality in any of the control birds.
aExperimental results from reference [1].
bExperimental results from reference [7].
cExperimental and control birds from phases I to III (including three control birds not previously dosed with meloxicam).
dFive of the six birds were experimental birds from Phase III and IV.1. The same birds were used for feeding tissue and oral gavage, with a 2-wk washout period between treatments (see Materials and Methods).
DOI: 10.1371/journal.pbio.0040066.t001
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body weight to 1 mg kg1 and then to the highest dose of 2 mg
kg1, which exceeds our estimate of the MLE (Protocol S1). At
the conclusion of each phase the results were evaluated, and
the study only proceeded to the next phase if all of the dosed
birds were healthy and had clinically normal serum concen-
trations of uric acid and alanine transferase (ALT), both of
which are known to be elevated beyond the normal range in
G. africanus after treatment with diclofenac [7]. In the fourth
phase, meloxicam was administered at 2 mg kg1 to captive G.
africanus in South Africa and wild vultures in Namibia,
thereby exposing a larger number of vultures from two
distinct populations to the estimated MLE of meloxicam in
the wild. The ﬁfth phase of the study simulated the natural
route of NSAID exposure, by feeding vultures with liver and
muscle tissue from cattle that had received a higher than
standard veterinary course of meloxicam treatment, with
daily injections over ﬁve days. The ﬁnal phase of testing was
to assess the safety of meloxicam to two of the three critically
endangered Asian vultures, by administering meloxicam by
gavage to captive G. bengalensis and G. indicus in India.
Results and Discussion
Safety Testing Using Captive G. africanus
In each of the ﬁrst three phases of our study, we
administered a single dose of meloxicam to ﬁve vultures by
gavage (oral administration into the crop via a 5-mm tube)
and gave sterilised water to three control birds by the same
method. The birds’ apparent health and serum parameters
were then assessed for 7 d after treatment. Dose rates in
Phases I to III were 0.5, 1, or 2 mg kg1, respectively, and were
set so that the highest dose just exceeded the likely MLE of
wild vultures (estimated as 1.83 mg kg1 vulture body weight;
Protocol S1). No ill health was observed in any of the 15
vultures treated with meloxicam at these three dose levels,
and all birds were alive and healthy at the end of the
experimental period (Table 1). There was a signiﬁcant loss of
body mass during the experimental period in Phases I, II, and
III (matched pairs t test; Phase I t7¼7.28, p , 0.001; Phase II t7
¼ 2.97, p , 0.05; Phase III t7¼ 2.96, p , 0.05). However, there
was no signiﬁcant difference between the meloxicam-dosed
and control birds in body mass change as a percentage of
initial mass in any of the three Phases (2-sample t test; Phase I
t6 ¼ 0.13, p . 0.89; Phase II t6 ¼ 0.46, p . 0.66; Phase III t6 ¼
0.61, p . 0.56). Because of this, and because no signiﬁcant loss
of body mass was observed in later phases of the experiment,
when birds were handled for sampling on fewer occasions
and not moved from their normal holding aviaries (see
below), we believe that the loss of body mass was most likely
due to the stress caused by handling and sampling, rather
than to meloxicam.
We compared the survival of vultures in these experiments
with that of two G. africanus treated with comparable doses of
diclofenac using the same methods [7]. In each phase, all ﬁve
meloxicam-treated vultures survived the experimental peri-
od, whereas both diclofenac-treated birds died with extensive
visceral gout. This represents a statistically signiﬁcant differ-
ence in death rate between the two drugs (2-tailed Fisher
exact test; 0/5 deaths versus 2/2 deaths, p ¼ 0.0476 in each
phase). However, because of the small sample sizes, these
results do not exclude the possibility that, in a worst-case
scenario, meloxicam might have caused appreciable mortality
if used on a larger sample. For example, with a total sample of
15 treated birds, statistically there could still be a 5% chance
of no birds dying, even if the true probability of death per
trial was as high as 18% ((1–0.18)15 ¼ 0.05). If only the ﬁve
birds treated in Phase III with more than the MLE are
considered, the failure to observe any deaths implies that
there could be a 5% probability that the true risk of death per
trial might be as high as 45% ((1–0.45)5¼0.05), which led us to
test a larger sample of birds in Phases IV and V (see below).
Although the survival of all of the meloxicam-treated
vultures in Phases I–III is not robust evidence of safety on its
own, it can be combined with information obtained by
sampling the blood of experimental and control birds. There
were no signiﬁcant differences in serum concentrations of
uric acid, ALT, albumin, and creatinine kinase (CK) between
treated and control groups in any of the three phases and for
any of the sampling times after dosing (Table S1). Inspection
of the magnitude of average differences in serum concen-
trations between treated and untreated birds showed no
indication of a systematic trend for any of the serum
constituents in relation to dose (Figure 1, Table S1). Since
the serum concentration of uric acid has been shown to be
elevated well beyond the normal range in G. africanus,
G.bengalensis, and Gyps fulvus treated with comparable fatal
doses of diclofenac [1,7], these observations provide sub-
stantial further evidence of safety.
Figure 1. Effect of Administration of Meloxicam and Diclofenac by
Gavage on Uric Acid in the Serum of Vultures
Blue symbols show the ratio of the geometric mean serum concentration
of uric acid for a group of Gyps africanus treated with meloxicam by
gavage to that for a control group treated with water and sampled at the
same time. Vertical lines show 95% confidence limits for the ratio. The
dashed horizontal line indicates a ratio of 1; i.e., no effect of treatment.
For each of six samplings after treatment, results are shown for
experiments in which different doses of drug were used. The fill colour
of the blue symbols indicates the meloxicam dose for the treated group:
white ¼ 0.5 mg kg1 (Phase I); light blue ¼ 1.0 mg kg1 (Phase II); dark
blue ¼ 2.0 mg kg1 (squares ¼ Phase III, diamonds ¼ Phase IV-2). Red
vertical bars show the maximum and minimum values of the equivalent
ratio for two groups of G. africanus, one group treated with 0.8 mg kg1
of diclofenac by gavage and another group treated with water and
sampled at the same time. Open red symbols show the ratio of the
serum concentration after treatment to that at the time of treatment for
three individual G. fulvus given 0.8 mg kg1 of diclofenac by gavage.
Filled red symbols show the ratio of the serum concentration 24 h post-
treatment to that 1 h post-treatment for three individual G. bengalensis
given 0.25 mg kg1 (squares) and 2.5 mg kg1 (diamond) of diclofenac by
gavage. Data from diclofenac experiments were taken from references
[1] and [7].
DOI: 10.1371/journal.pbio.0040066.g001
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Safety Testing Using Larger Numbers of Captive and Wild-
Caught G. africanus
Our objective in the next phase of the study was to narrow
the range of possible values of the true rate of meloxicam-
induced mortality that would be consistent with our data by
testing larger numbers of vultures with more than the likely
MLE. In this phase, we treated two groups of G. africanus. In
Phase IV.1, we used 14 long-term captive birds that had been
used more than 6 wk previously in Phases I to III (11 as
experimental birds and three as controls). We treated all 14
birds with meloxicam. In Phase IV.2, we captured 25 wild G.
africanus in Namibia and held them temporarily. Of these
birds, 21 were treated with meloxicam and four received
sterilised water and acted as controls. All treated birds in
Phase IV were given 2 mg kg1 of meloxicam by gavage (Table
1).
All 35 meloxicam-treated birds survived the 7-d exper-
imental period, and the wild-caught vultures used in Phase
IV.2 were all successfully released after the experiment. There
was no signiﬁcant change in the body mass of meloxicam-
treated birds between the beginning and end of the 7-d
period for either captive (matched pairs t test; t13¼ 0.29, p .
0.77) or wild-caught birds (matched pairs t test; t24¼ 1.68, p .
0.10). For the wild-caught birds there was also no signiﬁcant
difference in the percentage mass change of meloxicam-
dosed and control birds (2-sample t test; Phase I t23¼0.30, p.
0.77). Serum uric acid concentrations did not differ signiﬁ-
cantly between experimental and control groups and showed
no trend during the experimental period (Figure 1, Table S1).
Neck-drooping behaviour, similar to that seen in diclofenac-
dosed birds [7], was observed in the Phase IV.2 birds soon
after the collection of the second blood sample at 48 h
following treatment, and two birds lay on the ground.
However, neck-drooping was observed in both meloxicam-
dosed and control birds, and occurred during the heat of the
day. Hence, we consider that the neck-drooping we observed
was most likely to be a thermoregulatory activity [21] in
response to high ambient temperature and an elevation of
body temperature caused by the stress of handling and
sampling, rather than a response to meloxicam treatment. By
the end of the day, all birds (including the two recumbent
birds) had resumed a normal body posture. Neck-drooping
was not observed over the remaining 5 d of the trial. Hence,
we consider it to be a nonspeciﬁc response to stress caused by
heat or handling and not a speciﬁc response to NSAID
poisoning.
When the results from Phases III and IV of the study are
combined, 40 G. africanus were treated by gavage with more
than the likely MLE of meloxicam, and all survived with no ill
effects observed that were attributable to the drug. These
data indicate a 95% probability that the true probability of
death per trial consistent with these data was no higher than
7% ((10.07)40 ¼ 0.05). Taken together with the evidence of
lack of an effect of meloxicam on serum uric acid concen-
trations, these results indicate that meloxicam administered
by gavage does not cause appreciable mortality in G. africanus.
Safety Testing by Feeding G. africanus on Tissues of
Meloxicam-Treated Cattle
We wished to assess the possibility that although meloxicam
itself appears safe when administered to vultures at the MLE,
metabolites produced by treated cattle might be toxic. To test
this, we gave daily injections of 1.0 mg kg1 of meloxicam to
three cattle (Bos taurus) for 5 d. This is a higher dose level than
the two standard veterinary doses recommended in India (0.5
to 0.7 mg kg1 daily for ﬁve consecutive days). We slaughtered
the three cattle 8 h after the last injection and fed liver or
muscle to six captive G. africanus. An experiment by the
European Agency for the Evaluation of Medicinal Products
(EMEA) on Bos taurus found that tissue meloxicam concen-
trations in treated animals were higher in liver than in other
tissues tested, and peaked at the 8-h sampling period
(Protocol S1) [20]. In our experiment, concentrations of
parent meloxicam in cattle tissues at slaughter averaged 0.50
6 0.13 (6 1 standard deviation) mg kg1 for muscle and 8.12
6 1.10 mg kg1 for liver. Vultures consumed an average of
0.59 6 0.21 (6 1 standard deviation) kg of liver and 0.67 6
0.32 kg of muscle tissue, of the 1 kg with which they were each
provided, within the 48-h feeding period. On one occasion, a
bird ate all of the liver provided, and on two occasions, birds
ate the entire portion of muscle. The dose of parent
meloxicam ingested ranged from 0.03–0.15 mg kg1 vulture
body weight for muscle, and from 0.57–1.98 mg kg1 body
weight for birds feeding on liver.
Because we administered meloxicam for 5 d at a higher
dose (1.0 mg kg1) than in the EMEA study (0.7 mg kg1) [22],
the maximum dose ingested by a vulture (1.98 mg kg1 bw)
and the maximum cattle liver tissue concentrations (8.91 mg
kg1) are somewhat higher than those predicted from the
EMEA work (Protocol S1). For comparison, we also admin-
istered meloxicam by gavage at doses (1.18–2.45 mg kg1
vulture body weight) intended to be similar to those ingested
by birds feeding on liver. All six birds survived the treatments
and no ill effects or altered feeding behaviour was observed.
There was no signiﬁcant change in body mass between the
start and end of the 5-d experimental period for any of the
three treatment types (matched pairs t test; muscle t5¼ 1.00, p
. 0.36; liver t5 ¼ 2.44, p . 0.05; gavage t5¼ 1.46, p . 0.20).
Serum uric acid concentrations remained within the 95%
range observed in these individuals before treatment at both
sampling times and also within the similar 95% ranges for
uric acid for wild G. africanus captured in Namibia and
reported for G. africanus captured in Kenya [23] (Figure 2).
There was no signiﬁcant relationship between uric acid
concentration and meloxicam dose at 48 h or 96 h (OLS
regressions of log uric acid concentration on log meloxicam
dose for each of the three administration routes; p . 0.05 in
all cases). This was also the case when the log of the ratio of
the uric acid concentration after treatment to that before
treatment was used as the dependent variable. A more
elaborate analysis of variance in which log uric acid
concentration was modelled as a function of treatment
method, time period, and log meloxicam dose, with pretreat-
ment log uric acid concentration as a covariate, also gave no
indication of any signiﬁcant effect on serum uric concen-
tration of treatment with meloxicam by any of the three
routes (Protocol S2). The absence of mortality or elevation of
serum uric acid levels indicates that tissues of cattle treated
with meloxicam shortly before death are unlikely to be toxic
to G. africanus. The experiments using liver tissue are
particularly informative, because the quantity of liver eaten
by one bird approached the maximum meal size likely to be
consumed by a wild vulture, and this bird received a dose of
parent meloxicam in excess of the likely MLE.
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Safety Testing of Meloxicam on Endangered Asian Gyps
Although the experiments we have reported so far indicate
that meloxicam appears safe for G. africanus, this does not
exclude the possibility that it might be toxic to Asian Gyps
species, though this seems unlikely in view of the close
phylogenetic relationships within the genus [24] and the
similarity of the response to diclofenac of G. africanus and G.
bengalensis. We therefore administered meloxicam doses of 0.5
mg kg1 by gavage to three captive G. bengalensis and two G.
indicus and the MLE of 2.0 mg kg1 to three G. bengalensis and
two G. indicus. All 10 meloxicam-treated birds survived the 7-d
experimental period and they remain alive and healthy 4 mo
afterwards. None showed signs of ill health or abnormal
behaviour. There was no signiﬁcant change in body mass
during the experimental period (paired t-test; t5 ¼ 2.07, p .
0.09).
Hence, although the number of birds tested was small,
there is no indication of adverse effects of meloxicam on
these two species of Asian Gyps vultures.
Conclusions
The results of this study demonstrate that meloxicam is
much less toxic than diclofenac in at least three Gyps species,
including two of the critically endangered Asian species.
Indeed, we found no evidence that meloxicam administered
at doses exceeding our estimated likely MLE caused any
deaths or even elevation of serum uric acid concentrations.
Combining the results of this study with those from the
questionnaire to zoo veterinarians, a total of at least 88
individual birds from seven Gyps species are known to have
received meloxicam at various doses with no recognized
adverse effects. Hence, with this total of treated birds there is
a 95% chance that the per trial probability of mortality
caused by meloxicam is no higher than 3.5%. The observation
that serum concentrations of uric acid remain within the
normal range for all meloxicam dose rates adds substantially
to the evidence that meloxicam has low toxicity to G. africanus,
given that uric acid concentrations in this and two other Gyps
species were markedly elevated by lethal treatment with
diclofenac [1,7]. Preliminary results from the NSAID ques-
tionnaires indicate the safety of meloxicam to a wide range of
other vultures, raptors, and scavenging bird species, and to
date we know of more than 700 individuals from more than
30 species that have been treated with no apparent adverse
effects (unpublished data). This demonstrates that, at
Figure 2. Relationship of Uric Acid in Serum to the Dose of Meloxicam
and Diclofenac Administered and to the Administration Method
Serum concentration of uric acid in Gyps africanus 48 h (turquoise) and
96 h (blue) after treatment, in relation to the dose of meloxicam
administered per kg of vulture body weight. For comparison, the
geometric mean uric acid level (central horizontal line) and 95% range
(upper and lower horizontal lines) of the experimental birds 24 h before
treatment are shown. Also shown are serum concentrations of uric acid
24 h after treatment in G. africanus (red squares), G. bengalensis (red
diamonds), and G. fulvus (red triangles), to which diclofenac was
administered by various methods. The red line shows the regression
model fitted to these data. Panels show results for different methods of
administration of meloxicam to G. africanus: (A) gavage, (B) by feeding
liver from meloxicam treated cattle, (C) by feeding muscle from
meloxicam-treated cattle. Data from diclofenac experiments were taken
from references [1] and [7].
DOI: 10.1371/journal.pbio.0040066.g002
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recommended clinical dose levels, meloxicam is not toxic to a
wide range of avian species.
Any replacement for diclofenac must be effective for the
treatment of livestock as well as safe for vultures. Meloxicam
is one of the newer NSAIDs with preferential COX-2
inhibition, having analgesic, antipyretic, and anti-inﬂamma-
tory properties and a reduced risk of adverse effect on renal
function [16,25]. It is used to treat a variety of veterinary
ailments [26–30], and it is rated as a highly effective NSAID
[30–32]. Meloxicam is approved for human use in more than
80 countries, including India [33, 34]. It is used and licensed
as a veterinary drug in India, Europe, and North America
[35,36] and is already manufactured in India, where, like
diclofenac, it is available as both an injectable solution and
oral bolus. We hope that efforts to prevent diclofenac being
used to treat domestic livestock in the Indian subcontinent
and in other Gyps vulture range states will continue as a
matter of urgency. Where the availability of alternative drugs
is seen as a barrier to achieving this objective, we recommend
that governments consider advocating the use of meloxicam
as an alternative to diclofenac. Because vulture populations
are now very low and contamination of even a small
proportion of livestock carcasses is sufﬁcient to cause adverse
impacts on vulture populations [3], we also advocate
immediate intensiﬁcation of efforts to establish viable captive
populations of all three critically endangered species.
Materials and Methods
Trial animals. Nonreleasable captive vultures held at the de Wildt
Cheetah and Wildlife Trust (South Africa) were used for Phases I–III,
Phase IV.1, and Phase V. All birds at de Wildt were habituated to
captivity and eating regularly. In Phase IV.2, wild G. africanus (n¼ 25)
were captured using a walk-in trap located at a feeding site for
vultures in Namibia [37], run by the Rare and Endangered Species
Trust. Captive G. bengalensis and G. indicus for Phase VI of the trials
were held at the Bombay Natural History Society/Haryana State
Vulture Conservation Breeding Centre, Pinjore, Haryana State, India.
All birds used in Phase I–VI were adults and subadults. Ethical issues
relating to the experimental protocols were considered and approved
by the Animal Use and Care Committee and the Research Committee
of the Faculty of Veterinary Science of the University of Pretoria, the
Research Council of the Indian Veterinary Research Institute, and the
Board of the Bombay Natural History Society.
Housing and management. Birds used for Phases I–III were
transported from De Wildt to the University of Pretoria Biomedical
Research Centre (UPBRC) 7 d prior to the start of Phases I–III. At the
UPBRC, vultures were housed individually in primate cages (1.2 3
0.87 3 0.78 m) in an environmentally controlled room in which the
temperature (19–22 8C) and light cycle were kept constant and
humidity was allowed to vary with that outside (between 19% and
50% humidity). Vultures used for Phase IV.1 and Phase V were kept
at De Wildt, either within their normal holding aviaries (IV.1), or
within smaller isolation cages (V). Birds captured in Namibia (Phase
IV.2) were kept in the walk-in trap (11 3 5.5 3 5.5 m) [37], which
doubled as a holding aviary for the 7-d trial. Birds in India were
captured from their ﬂight aviaries 6 d before the start of the trials.
Five birds with pre-existing healed wing or leg injuries were held in
three small aviaries (43 33 2.5 m), the remaining two groups of ﬁve
birds were kept in two large holding aviaries (15 3 10 3 5 m). The
vultures were not fed for 24 h prior to treatment with meloxicam and
for up to 4 h afterwards. Thereafter, birds were fed according to their
normal feeding regime (200 g of meat daily at De Wildt and 1.0 kg of
meat every third or fourth day at Pinjore), with the exception of the
wild birds in Namibia, which were free to feed from the remains of an
adult donkey (Equus asinus) placed in the aviary. All meat was from
known sources, which were selected because we were conﬁdent that
they did not use any NSAIDs on their livestock.
Treatment and study design for oral gavage experiments. Phases I–
III followed a randomised, two-treatment–group, parallel-study
design with 24 nonreleasable captive G. africanus. In each phase (I–
III), vultures were randomly allocated to a meloxicam-treated group
(n¼5) and a control group (n¼3). In Phase IV.1, we treated 14 captive
vultures (no controls), and in Phase IV.2, we treated 21 wild vultures
and there were four control birds (Table 1). The vultures used in
Phase IV.1 had also been used in Phases I–III. To minimise the chance
of any effect of earlier treatment we ensured that the interval
between the end of one treatment and the beginning of the next was
at least 6 wk. To minimise the risk to captive G. bengalensis and G.
indicus in India, Phase VI of the meloxicam testing was staggered. Two
injured nonreleasable birds were ﬁrst treated by gavage with 0.5 mg
kg1 and one control bird was sham-dosed with sterilised water. After
48 h no apparent ill effects of the treatment were observed, so a
further three birds were dosed with 0.5 mg kg1, two injured
nonreleasable birds were dosed with 2 mg kg1, and a further two
control birds were sham-dosed. After another 48 h, three more birds
were dosed with 2 mg kg1 along with two ﬁnal control birds. All birds
(with the exception of birds fed muscle and liver tissue in Phase V)
were administered meloxicam as a single dose by oral gavage, with the
gavage tube ﬂushed with 2 ml of water. Control birds were sham-
treated by gavage with sterilised water. Birds were observed following
dosing for any regurgitation, but none occurred. The meloxicam used
came from .20 bottles of the product purchased from several
pharmacies in India. Meloxicam used in all phases of the study was
Melonex (Intas Pharmaceuticals, Ahmedebad, India). The stated
concentration of meloxicam (5,000 mg l1) within two bottles was
veriﬁed against pure meloxicam sodium salt (M-3935, Sigma-Aldrich,
St. Louis, Missouri, United States) through the high-performance
liquid chromatography (HPLC) analysis method described below and
found to be within the accepted 10% limits for pharmaceutical
products (4,500 mg l1 and 4,600 mg l1).
Phase V treatment and design. Phase V used a randomized, three-
period, three-treatment crossover design with a washout period of 2
wk between repeat dosing. Pharamacokinetic studies indicate that
meloxicam is rapidly metabolised in ﬁve other bird species
(elimination half-life [t½ el] of 0.5–2.4 h [20]) and eliminated within
12 h in G. africanus, and the 2-wk washout period was chosen to ensure
that no meloxicam residues were likely to be present on repeat
dosing. It was intended that each bird should receive all three
treatments in turn with a 2-wk washout period between treatments.
The three treatments were (1) feeding with muscle from a meloxicam-
treated cow, (2) feeding with liver from a meloxicam-treated cow, and
(3) oral gavage with a dose of meloxicam intended to be similar to
that taken in treatment (2). In each of the three treatment periods, all
three treatments were administered to two birds. Hence, two birds
were allotted at random to receive the sequence 1,2,3, two to receive
2,3,1, and two to receive 3,1,2. In each treatment period, the muscle
and liver was taken from one cow. In practice, an error was made so
that two birds received the wrong treatment in the ﬁnal period and
instead received 2,3,2 and 3,1,1. Hence, although all three treatments
were each administered on six occasions, and to two birds in each of
the three periods, two birds received the same type of treatment in
two periods. All six birds had previously been trained to consume
food from bowls. On the day of dosing, two birds were presented with
1 kg of muscle, two birds with 1 kg of liver tissue, and two birds were
dosed by oral gavage. Any food remaining after 48 h was removed and
weighed. Doses of meloxicam per kg vulture body weight were
estimated from the mass of tissue consumed and the concentration of
meloxicam within cattle tissues (see below). In the ﬁrst part of this
experiment, neither of the two birds given liver ate much of it, so all
six birds were routinely fed liver (between testing sessions) to
habituate them to eating liver in the trials.
Treatment of meloxicam-dosed cattle for Phase V. Three Bos taurus
steers of about 18 mo of age and weighing 300–400 kg were housed at
the UPBRC. Each animal received an intramuscular injection of
meloxicam at a dose of 1 mg kg1 on each of 5 d prior to slaughter. To
avoid unnecessary pain, the drug volume injected into any one site
never exceeded 20 ml, with all injections placed in the neck on the
left and right side on alternating days. This dose is twice the lower of
the two standard doses (0.5 and 0.7 mg kg1) recommended for
veterinary medicine in India. It is also higher than the dose (0.7 mg
kg1) administered in the EMEA study [22] that we used to calculate
the likely MLE of vultures to meloxicam in the wild (Protocol S1).
Cattle were slaughtered at the Veterinary Pathology Department,
University of Pretoria, by means of captive bolt to the brain followed
by the transection of the spinal cord at the level of the atlanto-
occipital junction, without subsequent exsanguination. Each animal
was slaughtered 8 h after the last meloxicam dose and on the day
prior to vulture feeding. The entire liver and quadriceps femoris
muscle were collected (sufﬁcient to supply liver and muscle for two
vultures) and refrigerated until feeding on the following day.
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Measuring meloxicam in tissues. Meloxicam concentrations in
liver and muscle tissues were measured through standard HPLC
methods calibrated against a known standard concentration of the
drug. Two 1-kg pieces of liver and muscle were cut from each
slaughtered animal. Five subsamples of tissue weighing 3–5 g (four
from the surface and one from the centre) were taken from each 1-kg
block and homogenised. Meloxicam was extracted from a 0.5-g
sample of the homogenised tissue, through homogenisation with 2 ml
of HPLC grade acetonitrile, which was then centrifuged at 1200 rpm
for 10 min and subsequently dried at 60 8C under a ﬂow of nitrogen.
This was followed up by a cleanup process using Waters Oasis
(Milford, Masachusetts, United States) HLB solid-phase extraction
cartridges [38]. The dried eluate was reconstituted in 50 ll MeOH and
100 ll 0.4% AcAc in MeOH:MeOH (40:60) and analysed in duplicate
by HPLC. For each homogenised sample, the mean of the four values
was used as the ﬁnal estimate of meloxicam concentrations.
Meloxicam sodium salt (M-3935, Sigma-Aldrich) was used for
calibration, with nine standards ranging from 100 lg to 50,000 lg
l1. The HPLC apparatus comprised a model 126 dual solvent pump,
model 168 diode array detector, and a 508 autosampler (Beckman
Instruments, Fullerton, California, United States). Chromatographic
separation was achieved using a Synergi MAX-RP C18 column (2.1
mm 3 150 mm, 5 lm; Phenomenex, Torrance, California, United
States) with UV detection at 275 nm, e.g., quantiﬁcation was done
with peak areas acquired from UV detection at 275 nm.
Observations on vultures. For all birds and all phases, body mass
was measured on the day of treatment (day 0) and at the end of each
trial period or when birds were returned to their normal aviaries. For
Phase I, II, III, and V, birds were weighed 12, 8, 12, and 5 d after
treatment, respectively. Birds from Phase IV.1, IV.2, and VI were
weighed on day 7. Body mass was measured to the nearest 0.5 kg
(South Africa and Namibia) and 0.1 kg (India). Observations for signs
of toxicity and abnormal feeding behaviour were undertaken daily. In
Phases I–III, blood (2.5 ml) was taken at 0 h (prior to dosing) and at 4,
12, 24, 48, 96, and 148 h after meloxicam treatment to quantify serum
uric acid and albumin concentrations and CK and ALT activity. In
Phase IV, blood (5 ml) was taken just prior to dosing and 48 h and 168
h afterwards to determine serum uric acid concentrations. Blood
sampling for Phase V was undertaken 24 h before feeding or dosing
by oral gavage, and at 48 h and 96 h after dosing or start of feeding.
Blood collection from vultures. In Phase I, blood samples were
taken by use of an indwelling catheter, placed in the jugular vein
while the vulture was under anaesthesia. This procedure was
considered to be unsatisfactory and was rapidly abandoned.
Subsequently, blood samples in all phases of the study were collected
by direct veno-puncture from the brachial or tarsal veins. A total of
approximately 15 ml of blood (about 3% of estimated blood volume)
was collected from each vulture over a 7-d period.
Measurement of serum constituents. Blood samples were spun at
1200 rpm for 15 min in a refrigerated centrifuge (4 8C) to separate
serum. Uric acid concentration was measured using ACE TM Uric
Acid Reagent, albumin concentration using the NExT TM Albumin
reagent, ALT activity using the Alfa Wasserman ALT, and CK using
the Alfa Wasserman CK Reagent e ACE TM clinical chemistry system
(Alfa Wassermann, West Caldwell, New Jersey, United States; Bayer
Health Care, Toronto, Canada). The analyses were performed by
means of the ACE TM and NExT TM Clinical Chemistry Systems (Alfa
Wassermann, Bayer Health Care).
Supporting Information
Protocol S1. Estimating Likely MLE of Meloxicam
Found at DOI: 10.1371/journal.pbio.0040066.sd001 (31 KB DOC).
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Note Added in Proof
The version of this paper that was ﬁrst made available on 31 January 2006
has been replaced by this, the deﬁnitive, version. In the ‘‘Treatment and study
design for oral gavage experiments’’ section of Materials and Methods, the
concentrations of meloxicam were incorrectly shown as 500 mg l1, 450 mg l1,
and 460 mg l1, but they have been corrected to 5,000 mg l1, 4,500 mg l1, and
4,600 mg l1, respectively. Additionally, Reference 7 was incorrectly shown as
7. Swan GE, Cuthbert R, Quevdeo M, Green RE, Pain DJ, et al. (2006) Toxicity of
diclofenac to Gyps vultures. Proc R Soc Lond B Biol Sci 2. DOI: 10.1098/
rsbl.2005.0425
but has been corrected to
7. Swan GE, Cuthbert R, Quevdeo M, Green RE, Pain DJ, et al. (2006) Toxicity of
diclofenac to Gyps vultures. Biol Lett. DOI: 10.1098/rsbl.2005.0425
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